Pittenger & Anderson Inc. trimmed its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 88.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,325 shares of the medical research company’s stock after selling 33,982 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Amgen were worth $973,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Dixon Hughes Goodman Wealth Advisors LLC acquired a new position in Amgen during the 4th quarter valued at approximately $26,000. Norwood Financial Corp acquired a new position in Amgen during the 4th quarter valued at approximately $28,000. PYA Waltman Capital LLC acquired a new position in Amgen during the 4th quarter valued at approximately $34,000. Econ Financial Services Corp acquired a new position in Amgen during the 4th quarter valued at approximately $34,000. Finally, Level Financial Advisors Inc. acquired a new position in Amgen during the 4th quarter valued at approximately $39,000. Institutional investors and hedge funds own 79.01% of the company’s stock.
A number of research analysts recently issued reports on AMGN shares. Jefferies Financial Group boosted their price objective on Amgen from $266.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, February 9th. Morgan Stanley reduced their price target on Amgen from $238.00 to $237.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. Barclays boosted their price target on Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a research report on Tuesday, April 12th. Wells Fargo & Company boosted their price target on Amgen from $210.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 9th. Finally, BMO Capital Markets reduced their price target on Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $240.40.
Shares of Amgen stock traded up $4.43 on Thursday, reaching $245.07. 186,355 shares of the company were exchanged, compared to its average volume of 3,181,804. The stock has a fifty day moving average price of $241.27 and a 200-day moving average price of $226.88. The firm has a market capitalization of $130.92 billion, a price-to-earnings ratio of 23.96, a price-to-earnings-growth ratio of 1.65 and a beta of 0.58. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. Amgen Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $258.45.
Amgen (NASDAQ:AMGN – Get Rating) last announced its earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.22 by $0.03. The company had revenue of $6.24 billion for the quarter, compared to analyst estimates of $6.09 billion. Amgen had a return on equity of 165.95% and a net margin of 21.75%. During the same period in the previous year, the firm earned $3.70 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 17.49 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Tuesday, May 17th will be given a dividend of $1.94 per share. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date is Monday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 76.38%.
Amgen Company Profile (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.